The phase II randomized trial, known as the CCTG CO.26 trial, was among the first studies to demonstrate that combined PD-L1 and CTLA-4 inhibition prolongs survival in patients with advanced refractory CRC. This evidence concerns the gene CTLA4 and colorectal carcinoma.